{"id":1021356,"date":"2026-11-16T10:42:49","date_gmt":"2026-11-16T15:42:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/"},"modified":"2026-11-16T10:42:49","modified_gmt":"2026-11-16T15:42:49","slug":"vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/","title":{"rendered":"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwpadr0 { padding-right: 0px }\n.bwrowaltcolor0 { background-color: #cceeff }\n.bwrowaltcolor1 { background-color: #d3d3d3 }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }\n.bwwidth18 { width: 18% }\n.bwwidth64 { width: 64% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>Loss per share narrows to $0.13 from $3.06<\/i><i> year-over-year, reflecting significantly lower reported losses, including the impact of substantial merger-related expenses in the prior-year quarter and changes in weighted-average shares outstanding.<\/i><\/li>\n<li><i>Strong liquidity position:<\/i><i> $6.96 million in cash and cash equivalents as of September 30, 2026, compared with $4.98 million at year-end 2025.<\/i><\/li>\n<li><i>VT-1953 development progresses:<\/i><i> Continued CMC and product development, preparation for further FDA engagement through a Type C meeting, and work on the response to the FDA&#8217;s request for additional information regarding orphan drug designation.<\/i><\/li>\n<\/ul>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nVyome Holdings, Inc. (Nasdaq: HIND, \u201cVyome\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.<\/p>\n<p>\nKrishna Gupta, Chairman of Vyome Holdings, stated, \u201cDuring the third quarter, Vyome continued to concentrate resources on the development of its lead program, VT-1953, while maintaining financial discipline and progressing selected activities across its pipeline. The Company ended September with approximately $7.0 million in cash and cash equivalents. Our emphasis remains on advancing defined development priorities and managing capital carefully.\u201d<\/p>\n<p>\nVenkat Nelabhotla, President and Chief Executive Officer of Vyome, stated, \u201cOur immediate priority remains VT-1953. During the quarter, we continued product development, CMC activities, clinical development planning, and preparatory work with prospective GMP manufacturing partners. Following the FDA\u2019s written feedback on our pre-IND briefing package, we have continued assembling the scientific, CMC, and clinical information required to support further discussion with the FDA through a Type C meeting before advancing our proposed clinical development program.\u201d<\/p>\n<p>\n\u201cWe are also reviewing the FDA\u2019s request for additional information and clarification relating to our VT-1953 Orphan Drug Designation application and preparing our response, including any necessary amendment. In parallel, formulation and CMC work continued for our VT-1908 topical ophthalmic program. We remain focused on the progression of our investigational programs and on selective opportunities within immuno-inflammatory disease, while making development and capital allocation decisions based on available data,\u201d concluded Mr. Nelabhotla.<\/p>\n<p><b>Third Quarter 2026 and Recent Corporate Highlights<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nVT-1953 regulatory development: Following the FDA\u2019s written response to the Company\u2019s pre-IND briefing package for VT-1953, a topical gel being developed to treat signs and symptoms of malignant fungating wounds the Company continued incorporating regulatory feedback and developing supporting scientific, CMC, and clinical information for planned engagement with the FDA through a Type C meeting for next steps.<\/p>\n<\/li>\n<li>\nVT-1953 product development and manufacturing: Continued clinical development planning, CMC and formulation-related activities, and preparatory work with prospective GMP manufacturing partners.<\/p>\n<\/li>\n<li>\nVT-1953 orphan drug application: Received FDA correspondence requesting additional information and clarification regarding the Company\u2019s Orphan Drug Designation application. The Company is reviewing the request and preparing its response as part of the ongoing review process.<\/p>\n<\/li>\n<li>\nVT-1953 Phase 2 study: Previously reported positive and statistically significant improvements in malodor, patient-reported impact of malodor on daily life, and lesion pain in an investigator-initiated Phase 2 study, with no treatment-emergent adverse events reported in that study.<\/p>\n<\/li>\n<li>\nVT-1908 ophthalmic program: Continued formulation and CMC development, GMP manufacturing planning. In October, the USPTO issued a Notice of Allowance for U.S. patent application claims covering formulations and methods associated with VT-1908.<\/p>\n<\/li>\n<li>\nFinance leadership: Appointed Jerry Leonard as Chief Financial Officer, effective September 1, 2026.<\/p>\n<\/li>\n<li>\nVyome&#8217;s Co-Founder and Director, Dr. Shiladitya Sengupta, was promoted to Professor of Medicine at Harvard Medical School in October 2026.<\/p>\n<\/li>\n<li>\nIn October 2026, Vyome received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering formulations and methods of use underlying VT-1908, its investigational topical ophthalmic program for anterior uveitis.<\/p>\n<\/li>\n<\/ul>\n<p><b>Financial Results for the Quarter Ended September 30, 2026<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nCash and cash equivalents were $6,956,822 as of September 30, 2026, compared with $4,982,333 as of December 31, 2025.<\/p>\n<\/li>\n<li>\nTotal assets were $8,611,672 as of September 30, 2026; Total stockholders\u2019 equity was $6,545,927, compared with $3,762,017 as of December 31, 2025.<\/p>\n<\/li>\n<li>\nThird-quarter revenue was $57,998, compared with $34,627 in the prior-year period. Revenue for the first nine months of 2026 was $116,544, compared with $283,163 for the same period in 2025.<\/p>\n<\/li>\n<li>\nThird-quarter operating expenses totaled $1,047,943, including $409,831 in research and development and $635,410 in selling, general and administrative expenses. Operating expenses in the prior-year quarter totaled $8,592,360, including $7,705,533 in merger-related transactional fees, $39,677 in research and development and $844,344 in selling, general and administrative expenses.<\/p>\n<\/li>\n<li>\nThe third-quarter net loss was $930,325, compared with $8,595,300 in the prior-year quarter.<\/p>\n<\/li>\n<li>\nNet loss of the Company attributable to owners was $885,408, or $0.13 per basic and diluted share, compared with $8,433,811, or $3.06 per basic and diluted share, in the prior-year quarter. The reduction in reported loss per share compared with the prior-year quarter should be viewed in the context of merger-related charges in the 2025 period and changes in weighted-average shares outstanding.<\/p>\n<\/li>\n<li>\nFor the nine months ended September 30, 2026, total net loss was $2,635,529 compared with $9,198,033 in 2025. Loss per basic and diluted share was $0.37, compared with $9.82 in the prior-year period.<\/p>\n<\/li>\n<\/ul>\n<p>\nComplete financial results are available in the Company\u2019s Quarterly Report on Form 10-Q for the period ended September 30, 2026, filed with the U.S. Securities and Exchange Commission.<\/p>\n<p><b>About Vyome Holdings, Inc.:<\/b><\/p>\n<p>\nVyome is building the world\u2019s premier platform spanning the US-India innovation corridor. Vyome\u2019s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety.<\/p>\n<p>\nTo learn more, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vyometx.com%2F&amp;esheet=54641896&amp;newsitemid=20261116794031&amp;lan=en-US&amp;anchor=www.vyometx.com&amp;index=1&amp;md5=fd8fcb247ffcad92d519d5088287419b\">www.vyometx.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements made in this press release are \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cshall,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cwould,\u201d \u201cpositioned,\u201d \u201cfuture,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201coutlook,\u201d \u201ccontinue,\u201d \u201cseek\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements include, but are not limited to, statements contained in this press release relating to Vyome\u2019s business strategy, Vyome\u2019s clinical development plans and expected timelines, the expected therapeutic potential of Vyome\u2019s product candidates and pipeline assets, Vyome\u2019s intellectual property strategy, Vyome\u2019s future operating results, and Vyome\u2019s liquidity and capital resources outlook. Forward-looking statements are based on Vyome\u2019s current expectations and assumptions regarding Vyome\u2019s business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Vyome\u2019s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Vyome cautions you, therefore, against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, Vyome\u2019s ability to raise capital to fund continuing operations; the timing and outcome of Vyome\u2019s interactions with the FDA, including the planned Type C meeting and the FDA\u2019s review of Vyome\u2019s Orphan Drug Designation application for VT-1953; Vyome\u2019s reliance on third-party manufacturing partners; the risk that results of the investigator-initiated Phase 2 study of VT-1953 may not be predictive of future clinical results; our ability to successfully design, initiate, enroll, and complete clinical trials; our ability to successfully advance VT-1908 and our other pipeline programs; our ability to protect Vyome\u2019s intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and products; Vyome\u2019s ability to develop and commercialize products and services; changes in government regulation; and other factors relating to Vyome\u2019s industry, operations and results of operations described in Vyome\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, Vyome\u2019s Quarterly Reports on Form 10-Q, Vyome\u2019s Current Reports on Form 8-K and subsequent filings with the SEC. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause Vyome\u2019s actual results to differ may emerge from time to time, and it is not possible for Vyome to predict all of them. Vyome cannot guarantee future results, levels of activity, performance, or achievements. Vyome assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as may be required under applicable securities law.<\/p>\n<p><b>SUMMARY FINANCIAL STATEMENTS<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>SUMMARY OF CONDENSED CONSOLIDATED BALANCE SHEETS AS OF<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwrowaltcolor0 bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwpadl0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>September 30, 2026<\/b><\/p>\n<p class=\"bwalignr bwcellpmargin\"><b>(Unaudited)<\/b><\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwpadl0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>December 31, 2025<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCash and cash equivalents<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ 6,956,822<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ 4,982,333<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPrepaid and Other current assets<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n641,602<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n455,988<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nLong term assets<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1,013,248<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1,058,856<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal assets<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n8,611,672<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n6,497,177<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nLiabilities<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2,065,745<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2,735,160<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal Stockholders\u2019 equity (deficit)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ 6,545,927<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ 3,762,017<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal liabilities and stockholders\u2019 equity<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ 8,611,672<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ 6,497,177<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>SUMMARY OF UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwrowaltcolor0 bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Three months ended<\/b><\/p>\n<p class=\"bwalignr bwcellpmargin\"><b>September 30, 2026<\/b><\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Three months ended<\/b><\/p>\n<p class=\"bwalignr bwcellpmargin\"><b>September 30, 2025<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nRevenues<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ 57,998<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ 34,627<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCost of goods sold<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(31,196)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(16,577)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGross profit<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n26,802<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n18,050<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating expenses<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1,047,943<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n8,592,360<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating loss<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(1,021,141)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(8,574,310)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nInterest and other income (expenses), net<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n90,816<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(20,990)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet loss<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (930,325)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (8,595,300)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet loss attributable to non-controlling interest<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(44,917)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(161,489)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet loss attributable to owners of the Company<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (885,408)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (8,433,811)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nLoss per common share \u2014 basic and diluted<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (0.13)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (3.06)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nWeighted average shares outstanding<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n7,018,528<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2,758,490<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>SUMMARY OF UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwrowaltcolor0 bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Nine months ended<\/b><\/p>\n<p class=\"bwalignr bwcellpmargin\"><b>September 30, 2026<\/b><\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Nine months ended<\/b><\/p>\n<p class=\"bwalignr bwcellpmargin\"><b>September 30, 2025<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nRevenues<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ 116,544<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ 283,163<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCost of goods sold<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(61,439)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(86,458)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGross profit<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n55,105<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n196,705<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating expenses<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,068,752<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n9,294,201<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating loss<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(3,013,647)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(9,097,496)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nInterest and other income (expenses), net<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n378,118<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(100,537)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet loss<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (2,635,529)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (9,198,033)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet loss attributable to non-controlling interest<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(101,655)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(161,489)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet loss attributable to owners of the Company<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (2,533,874)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (9,036,544)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nLoss per common share \u2014 basic and diluted<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (0.37)<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18 bwrowaltcolor1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ (9.82)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth64\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nWeighted average shares outstanding<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n6,910,311<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n919,754<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n\u00a0<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261116794031\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261116794031\/en\/<\/a><\/span><\/p>\n<p>\nMedia:\u2028<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@vyometx.com\">ir@vyometx.com<\/a><\/p>\n<p>\nVisit us on social media:<br \/>\n<br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fvyometx%2F&amp;esheet=54641896&amp;newsitemid=20261116794031&amp;lan=en-US&amp;anchor=Facebook&amp;index=2&amp;md5=a7d3b315a2b85699e87194d01a255d85\">Facebook<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FVyomeInc&amp;esheet=54641896&amp;newsitemid=20261116794031&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=3697e72b18a08ae06b38034fa143f947\">X<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fvyome-holdings%2F&amp;esheet=54641896&amp;newsitemid=20261116794031&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=fc80f603417e7d42b266075dfff7e52d\">LinkedIn<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261116794031\/en\/2972243\/3\/Vyome_New_Logo_2025.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program Loss per share narrows to $0.13 from $3.06 year-over-year, reflecting significantly lower reported losses, including the impact of substantial merger-related expenses in the prior-year quarter and changes in weighted-average shares outstanding. Strong liquidity position: $6.96 million in cash and cash equivalents as of September 30, 2026, compared with $4.98 million at year-end 2025. VT-1953 development progresses: Continued CMC and product development, preparation for further FDA engagement through a Type C meeting, and work on the response to the FDA&#8217;s request for additional information regarding orphan drug designation. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Vyome Holdings, Inc. (Nasdaq: HIND, \u201cVyome\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on immuno-inflammatory &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021356","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program Loss per share narrows to $0.13 from $3.06 year-over-year, reflecting significantly lower reported losses, including the impact of substantial merger-related expenses in the prior-year quarter and changes in weighted-average shares outstanding. Strong liquidity position: $6.96 million in cash and cash equivalents as of September 30, 2026, compared with $4.98 million at year-end 2025. VT-1953 development progresses: Continued CMC and product development, preparation for further FDA engagement through a Type C meeting, and work on the response to the FDA&#8217;s request for additional information regarding orphan drug designation. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Vyome Holdings, Inc. (Nasdaq: HIND, \u201cVyome\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on immuno-inflammatory &hellip; Continue reading &quot;Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T15:42:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program\",\"datePublished\":\"2026-11-16T15:42:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/\"},\"wordCount\":1610,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/\",\"name\":\"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-16T15:42:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/","og_locale":"en_US","og_type":"article","og_title":"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program - Market Newsdesk","og_description":"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program Loss per share narrows to $0.13 from $3.06 year-over-year, reflecting significantly lower reported losses, including the impact of substantial merger-related expenses in the prior-year quarter and changes in weighted-average shares outstanding. Strong liquidity position: $6.96 million in cash and cash equivalents as of September 30, 2026, compared with $4.98 million at year-end 2025. VT-1953 development progresses: Continued CMC and product development, preparation for further FDA engagement through a Type C meeting, and work on the response to the FDA&#8217;s request for additional information regarding orphan drug designation. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Vyome Holdings, Inc. (Nasdaq: HIND, \u201cVyome\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on immuno-inflammatory &hellip; Continue reading \"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T15:42:49+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program","datePublished":"2026-11-16T15:42:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/"},"wordCount":1610,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/","name":"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-16T15:42:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116794031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-reports-sharp-reduction-in-q3-2026-loss-per-share-advances-lead-vt-1953-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021356"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021356\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}